The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Blocking the Inflammatory Route
Anterior Segment Research & Innovations News

Blocking the Inflammatory Route

New research looks at a more selective approach to controlling ocular inflammation

11/10/2026 1 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll
Objective:

To investigate whether limiting leukocyte migration into retinal tissue can reduce inflammation in a mouse model of endotoxin-induced uveitis (EIU).

Approach:
  • Neutrophil depletion: Researchers assessed CCR2-positive monocyte infiltration and disease measures after depleting neutrophils before inducing EIU.
  • PECAM-1 blockade: They treated mice with an anti-PECAM antibody and evaluated leukocyte migration, clinical scores, and retinal histology.
Key Findings:
  • Neutrophil depletion increased retinal infiltration by CCR2-positive monocytes at 24 and 72 hours. Histologic measures improved, but clinical scores did not significantly improve.
  • Anti-PECAM treatment significantly reduced neutrophil and T-cell transmigration into the retina; imaging showed neutrophils retained within retinal vessels.
  • Compared with controls, anti-PECAM-treated mice had significantly lower blinded clinical scores and reduced leukocyte infiltration, edema, and hemorrhage on histology.
  • PECAM blockade inhibited approximately 64% of neutrophil transmigration.
Interpretation:

The authors propose that selectively limiting leukocyte entry into ocular tissue could preserve more systemic immune function than broader immunosuppression, but this possibility was not directly tested.

Limitations:
  • The study used an acute mouse model of EIU.
  • Anti-PECAM was administered before symptoms developed.
  • The investigators examined retinal vasculature rather than leukocyte trafficking throughout the uvea.
  • Translation of the mechanism into a practical treatment for human uveitis remains undetermined.
Conclusion:

PECAM-1 blockade reduced leukocyte entry and improved clinical and histologic measures in this preclinical EIU model. Further studies are needed to assess its relevance to human uveitis.

Sources:
  • Article context provided in the prompt

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: